Abstract: Endothelin is closely associated with kidney diseases. Activation of endothelin receptor A promotes vasoconstriction, inflammation, fibrosis, and cell proliferation, leading to kidney damage. By antagonizing the endothelin receptors, renal function can be protected. Currently, endothelin receptor antagonists are primarily used to treat pulmonary arterial hypertension. However, numerous clinical trials have confirmed that endothelin receptor antagonists are significantly effective in reducing proteinuria and protecting renal function. They are promising as a new type of medication for the treatment of various kidney diseases.

Key words: endothelin receptor antagonists, glomerular diseases, renal vascular diseases